Navigation Links
Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects
Date:9/24/2009

ort our commitment to continue to develop farletuzumab for ovarian cancer," said Nicholas C. Nicolaides, Ph.D., President and CEO of Morphotek. "Our research with farletuzumab is consistent with our human health care (hhc) mission - addressing unmet medical needs by developing new treatment options that will improve the lives of patients."

Study Details

The primary objectives of the open-label Phase II study included: to measure overall response rate (ORR), to compare the length of a subject's second remission with her first remission and to measure change in CA-125 level.( )Approximately 20 centers in the United States, Germany and the Netherlands participated in the study.

Thirty-nine (88.6%) of the 44 eligible subjects receiving farletuzumab in combination with platinum and taxane had their CA-125 blood levels normalized, and three additional subjects had a 50% decrease.( )(According to the National Cancer Institute, CA-125 is a tumor marker frequently elevated in ovarian cancer. It is typically used to evaluate tumor response, as CA-125 levels generally correlate with tumor activity.) In nine (20.5%) of these 44 subjects, the second remission was equal to or longer than the first remission.

About Ovarian Cancer

Ovarian cancer forms in the tissue of the ovary. Most ovarian cancers are epithelial carcinomas (cancer that begins in the cells on the surface of the ovary).

Ovarian cancer, which ranks fifth as the cause of cancer deaths in women, usually grows asymptomatically before it is discovered. In Europe, it is estimated that there are 61,000 cases of ovarian cancer each year. The National Cancer Institute estimates that there were 21,550 new cases of ovarian cancer in the United States in 2009 and 14,600 deaths from the disease.

About Farletuzumab

Farletuzumab (MORAb-003) is a humanized monoclonal antib
'/>"/>

SOURCE Morphotek(R), Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
2. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
3. ClariVein(TM) Catheter for Varicose Veins: Further Clinical Trial Results to Be Presented
4. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
5. New Micro-Bland Embolization Technique with Embozene(TM) Microspheres to Be Presented at the International Medical Conference in Lisbon, Portugal
6. QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting
7. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2009
8. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
9. Late Breaking Clinical Trials Presented at HFSA 13th Annual Scientific Meeting
10. Study on PLC Systems TMR Therapy With Stem Cells Presented at ESC 2009
11. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number of ... compound, LB‑100, is being conducted, has been expanded from 1 ... M.D., the founder and President of Lixte, said that, "the ... site. Accrual of patients, however, was slower than projected. The ...
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ), ... innovative proprietary products to treat voiding dysfunctions, today reported ... 31, 2014.  Global revenue for the Company,s ... million, a new quarterly revenue record, as compared to ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... 22 Sciona, Inc., a leader in the,science ... pivotal study,published by Nutrition Journal, which demonstrates substantial ... levels as a result of,personalizing patients, diets based ... to demonstrate the efficacy of applying,nutrigenetics to long ...
... 22 Facet Solutions, Inc. announced,today that ... from the,Department of Bioengineering at the University ... System (AFRS(TM)) has shown biomechanical,advantages when compared ... testing was to compare the range of ...
Cached Medicine Technology:Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels 2Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels 3Facet Solutions' AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing 2
(Date:1/22/2015)... California (PRWEB) January 22, 2015 The City of ... at 10 a.m., to commemorate the 42nd anniversary of the Supreme ... States. , “It’s been 42 years since the Roe vs. Wade ... is still as present as ever,” said City of West Hollywood ...
(Date:1/22/2015)... 23, 2015 VogueQueen is a seasoned and ... and many designers are thrilled to have it lead the ... its new collection of prom dresses for the global market. ... the strategic vision and he focuses on continuing the goal ...
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
(Date:1/22/2015)... 2015 Joan Lunden, award-winning American journalist, ... the upcoming 32nd Annual Miami Breast Cancer Conference ... Resource®, LLC (PER®) , shares that “a fast-growing, virulent” ... if she had not followed up her clean mammogram ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... lining in rats who,d had ovaries removed , , THURSDAY, ... the effects of menopause in rats, according to a ... with soy aglycons of isoflavone (SAI) -- a group ... boosted the anti-oxidative abilities of the liver, and prevented ...
... and Gynaecologists (RCOG) and the Liverpool School of Tropical ... and newborn health in five target countries - Zimbabwe, ... year more than half a million women and four ... childbirth, nearly all in developing countries in Asia and ...
... conducted at the University of L,Aquila in Italy and ... first to show that black tea consumption - depending ... reduced both blood pressure and arterial stiffness, suggesting a ... health.Using a cohort of 19 healthy men (mean age ...
... just announced a flexible payment plan for its Barcode Inventory, Asset, Evidence ... with twelve (12) to sixty (60) month financing. These finance options ... enables our customers to be more efficient and effective. , ... San ...
... Services simplifies physician practices and makes them as ... clients who demand results by securing client relationships ... the right tools to providers, offices that become ... less billing and coding errors, which results in ...
... called Safe Stem Cells NOW! was formed in response to the ... and should be regulated as such. The patient group believes ... availability of therapies without adding any significant patient safety. , ... ...
Cached Medicine News:Health News:£2.8 million grant to raise standards in maternal and newborn health 2Health News:New Research Suggests Drinking as Little as One Cup of Black Tea Per Day May Help Maintain Cardiovascular Function and Heart Health 2Health News:New Research Suggests Drinking as Little as One Cup of Black Tea Per Day May Help Maintain Cardiovascular Function and Heart Health 3Health News:New Research Suggests Drinking as Little as One Cup of Black Tea Per Day May Help Maintain Cardiovascular Function and Heart Health 4Health News:ASAP Systems now Offers Flexible Payment Options for its Barcode Inventory, Asset and Evidence Tracking Solutions Through a Strategic Microsoft Financing™ Partnership 2Health News:Patient Movement Forms in Opposition to FDA Position that the Patient's Own Stem Cells are Drugs 2Health News:Patient Movement Forms in Opposition to FDA Position that the Patient's Own Stem Cells are Drugs 3
... personal-sized Thermal Cycler is the ideal instrument for ... range of PCR applications. Get Applied ... Save lab space without sacrificing results. ... Industry-Standard PCR Technology You Can Afford ...
... ep Extremely fast heating and cooling ... Intuitive graphic programming Can be used ... or a PC-controlled network Heated lid with ... motorized lid for integration into fully automated ...
PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
PxE thermal Cycler. 0.5ml block holds 48 0.5 ml tubes or 96 0.3 ml tubes. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User frien...
Medicine Products: